SCHEMBL2660802

SCHEMBL2660802

COCC(O)Cn1ccc(N)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
SCN9A Q15858 1/20 0.33
PDE10A Q9Y233 2/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 2/20 0.32
TYK2 P29597 2/20 0.32
JAK3 P52333 2/20 0.32
HPGD P15428 4/20 0.32
KDM4E B2RXH2 2/20 0.32
TSHR P16473 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31030377 0.82 HPGD (0.38) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL8216088 0.81 HTT (0.49) MAPTALDH1A1TDP1L3MBTL1KDM4E
SCHEMBL1080403 0.80 ALDH1A1 (0.40) MAPTALDH1A1TDP1MEN1KMT2A
SCHEMBL1067067 0.80 ALDH1A1 (0.40) MAPTALDH1A1TDP1MEN1KMT2A
SCHEMBL1067071 0.80 ALDH1A1 (0.40) MAPTALDH1A1TDP1MEN1KMT2A
Hydrochloric Acid SCHEMBL1082148 0.78 ALDH1A1 (0.39) MAPTALDH1A1TDP1MEN1KMT2A
SCHEMBL24884401 0.78 ALDH1A1 (0.42) ALDH1A1TDP1MEN1KMT2AL3MBTL1
SCHEMBL1863535 0.78 ALDH1A1 (0.42) ALDH1A1TDP1MEN1KMT2AL3MBTL1
SCHEMBL25619573 0.78 ALDH1A1 (0.42) ALDH1A1TDP1MEN1KMT2AL3MBTL1
SCHEMBL2151487 0.77 DNM1 (0.43) MAPTALDH1A1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
EP-2157859-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE Takeda Pharmaceutical Company Limited (JP) 2010-03-03 EP disclosed
WO-2008156757-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE GCKR, GCK, KHK MAPT 4750/4885ALDH1A1 2440/4885TDP1 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.